D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) have been discovered in several cancer types and cause the neurometabolic syndrome D2-hydroxyglutaric aciduria (D2HGA). The mutant enzymes exhibit neomorphic activity resulting in production of D2-hydroxyglutaric acid (D-2HG). To study the pathophysiological consequences of the accumulation of D-2HG, we generated transgenic mice with conditionally activated IDH2 R140Q and IDH2 R172K alleles. Global induction of mutant IDH2 expression in adults resulted in dilated cardiomyopathy, white matter abnormalities throughout the central nervous system (CNS), and muscular dystrophy. Embryonic activation of mutant IDH2 resulted in more pronounced phenotypes, including runting, hydrocephalus, and shortened life span, recapitulating the abnormalities observed in D2HGA patients. The diseased hearts exhibited mitochondrial damage and glycogen accumulation with a concordant up-regulation of genes involved in glycogen biosynthesis. Notably, mild cardiac hypertrophy was also observed in nude mice implanted with IDH2 R140Q-expressing xenografts, suggesting that 2HG may potentially act in a paracrine fashion. Finally, we show that silencing of IDH2 R140Q in mice with an inducible transgene restores heart function by lowering 2HG levels. Together, these findings indicate that inhibitors of mutant IDH2 may be beneficial in the treatment of D2HGA and suggest that 2HG produced by IDH mutant tumors has the potential to provoke a paraneoplastic condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 4×
“Mutations in IDH1/2 may provide a selective advantage at the initial stages of cellular transformation by altering epigenetic reprogramming (Figueroa et al. 2010; Turcan et al. 2012); somewhat paradoxically, GBM patients with IDH mutations have a better prognosis compared with patients with…”
BackgroundSelf-citationIDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Self-citationIDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974 · cited 7×
“Oncologyfocused studies suggest that 2HG accumulation inhibits aKG-dependent dioxygenases, including the TET family methylcytosine dioxygenases, and the JmjC domaincontaining histone demethylases, thereby causing a global DNA and histone hypermethylation phenotype (Figueroa et al. 2010; Xu et al. 2011; Lu et al. 2012;…”
InfluentialGlioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 1×
“Initial reports found increases in HIF1a levels in gliomas with IDH1 mutations compared with IDH wild-type tumors (Zhao et al. 2009; Xu et al. 2011), while a later study showed a decrease in HIF1a activation through the 2HG-mediated activation of aKGdependent prolyl hydroxylases (PHDs or EglNs)…”
BackgroundAnalysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036 · cited 1×
“…and subsets of chondrosarcoma, cholangiocarcinoma, acute lymphoblastic leukemia (ALL), prostate cancer, melanoma, and nonsmall-cell lung cancer (Balss et al. 2008; Kang et al. 2009; Yan et al. 2009; Abbas et al. 2010; Green and Beer 2010; Amary et al. 2011a,b; Sequist et al. 2011; Shibata et…”
BackgroundAmary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
Self-citation( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703 · cited 1×
“…et al. 2012; Turcan et al. 2012) and has been shown to directly modulate chromatin states by inhibiting the function of both TET family enzymes involved in DNA demethylation (Figueroa et al. 2010; Xu et al. 2011; Losman et al. 2013) and the Jumonji family of histone demethylases (Lu et al. 2012).”
BackgroundSelf-citationIDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513 · cited 4×
“Unlike recent findings in IDH1 mutant mice (Sasaki et al. 2012), we did not observe significant changes in the maturation of collagen type IV in the IDH2 mutant hearts (data not shown).”
BackgroundResultInfluentialBCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1
Tönjes, M., Barbus, S., Park, Y. J., Wang, W., Schlotter, M., Lindroth, A. M., Pleier, S. V., Bai, A. H. C., Karra, D., Piro, R. M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3217 · Cited by 486 · cited 2×
“2011) and branched chain amino acid metabolism (Tonjes et al. 2013).”
BackgroundProfiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., He, Y., Bigner, D. D., Vogelstein, B., & Yan, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019393108 · Cited by 449 · cited 3×
“Furthermore, some metabolic processes are affected by 2HG accumulation, leading to alterations in the TCA cycle (Reitman et al. 2011) and branched chain amino acid metabolism (Tonjes et al.”
BackgroundImplementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr489 · Cited by 370 · cited 2×
“Elevated 2HG resulting from recurrent mutations in the mitochondrial metabolic enzyme IDH2 (R140Q and R172K) or its cytosolic counterpart, IDH1, has also been associated with the development of several cancers: glioma, acute myeloid leukemia (AML), and subsets of chondrosarcoma, cholangiocarcinoma, acute lymphoblastic…”
BackgroundProgress in understanding 2‐hydroxyglutaric acidurias
Kranendijk, M., Struys, E. A., Salomons, G. S., Van der Knaap, M. S., & Jakobs, C. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9462-5 · Cited by 292 · cited 1×
“Moreover, as in mice with expression of an IDH1R132H knock-in allele in the hematopoietic cells (Sasaki et al. 2012), the cardiomyocytes from IDH2 mutant mice did not show altered expression of hypoxia-responsive genes (Liu et al. 2012) upon microarray analysis (data not shown).”
BackgroundL‐2‐Hydroxyglutaric aciduria: an inborn error of metabolism?
Duran, M., Kamerling, J. P., Bakker, H. D., van Gennip, A. H., & Wadman, S. K. (1980) · Journal of Inherited Metabolic Disease · doi:10.1007/bf02312543 · Cited by 226 · cited 2×
“…D,L2-hydroxyglutaric aciduria (D,L-2HGA) are rare neurodegenerative disorders resulting from accumulation of 2HG isomers (Chalmers et al. 1980; Duran et al. 1980) that are produced as metabolic intermediates in reactions catalyzed by L-malate dehydrogenase and hydroxyacid– oxoacid…”
BackgroundIDH2 Mutations in Patients with d -2-Hydroxyglutaric Aciduria
Kranendijk, M., Struys, E. A., van Schaftingen, E., Gibson, K. M., Kanhai, W. A., van der Knaap, M. S., Amiel, J., Buist, N. R., Das, A. M., de Klerk, J. B., et al. (2010) · Science · doi:10.1126/science.1192632 · Cited by 195 · cited 4×
“Cardiomyopathy requiring treatment is frequently observed in type II D2HGA patients (Kranendijk et al. 2010b, 2012).”
BackgroundResultInfluentialRocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-401 · Cited by 171 · cited 2×
“…nearly all IDH mutations in human tumors are invariably concurrent with additional genetic alterations (such as inactivation of TP53 or P14ARF) or deletion of 1p/19q in glioma patients (Ichimura et al. 2009) and with NRAS, ASXL1, or FLT3 mutations in leukemia patients (Rocquain et al. 2010).”
BackgroundD‐2‐hydroxyglutaric aciduria: Case report and biochemical studies
Chalmers, R. A., Lawson, A. M., Watts, R. W. E., Tavill, A. S., Kamerling, J. P., Hey, E., & Ogilvie, D. (1980) · Journal of Inherited Metabolic Disease · doi:10.1007/bf02312516 · Cited by 135 · cited 4×
“Although it has been >30 years since the first report of DH2GA (Chalmers et al. 1980), the progression of the disease is still poorly understood, and there is no effective treatment (Kranendijk et al.”
BackgroundInfluential
Cited by
Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy
Diguet, N., Trammell, S. A. J., Tannous, C., Deloux, R., Piquereau, J., Mougenot, N., Gouge, A., Gressette, M., Manoury, B., Blanc, J., et al. (2018) · Circulation · doi:10.1161/circulationaha.116.026099 · Cited by 358
Metabolic signatures of cancer cells and stem cells
Intlekofer, A. M., & Finley, L. W. S. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0032-0 · Cited by 322
Gonzalvez, F., Vincent, S., Baker, T. E., Gould, A. E., Li, S., Wardwell, S. D., Nadworny, S., Ning, Y., Zhang, S., Huang, W.-S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1683 · Cited by 190
Self-citationde Boer, R. A., Hulot, J.-S., Tocchetti, C. G., Aboumsallem, J. P., Ameri, P., Anker, S. D., Bauersachs, J., Bertero, E., Coats, A. J. S., Čelutkienė, J., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2029 · Cited by 183
Self-citationMolenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., van Noorden, C. J. F., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 182
Metadata
- Authors
- Akbay, E. A., Moslehi, J., Christensen, C. L., Saha, S., Tchaicha, J. H., Ramkissoon, S. H., Stewart, K. M., Carretero, J., Kikuchi, E., Zhang, H., Cohoon, T. J., Murray, S., Liu, W., Uno, K., Fisch, S., Jones, K., Gurumurthy, S., Gliser, C., Choe, S., Keenan, M., Son, J., Stanley, I., Losman, J. A., Padera, R., Bronson, R. T., Asara, J. M., Abdel-Wahab, O., Amrein, P. C., Fathi, A. T., Danial, N. N., Kimmelman, A. C., Kung, A. L., Ligon, K. L., Yen, K. E., Kaelin, W. G., Bardeesy, N., & Wong, K.-K.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-03-01
- Volume
- 28
- Issue
- 5
- Pages
- 479-490
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2027834197
- Cited by
- 87
- References
- 20
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.